Prostate Cancer

Review Article

Using Molecular Markers to Help Predict Who Will Fail after Radical Prostatectomy

Table 2

p53, bcl-2, and outcomes after radical prostatectomy. The table indicates whether p53 and bcl-2 was positive on univariate or multivariate analysis for predicting failure. The failure of the entire cohort is given and then the outcomes for patients where the marker was elevated versus not elevated.


Study	#pts	Med (mean) months f/u	Include LN+ ()	Include Adj RX ()	Definition of failure^@	Univariate positive	Multivariate positive	Group overall failure	Marker elevated outcome	Marker not elevated outcome

P53
Theodorescu et al. [16]	71	127	Yes (1)	No	Clinical, PSA > 0.2	Yes	Yes	51% failed	15-yr cause-specific 38%	15-yr cause-specific 87%
Kuczyk et al. [17]	76	50	Yes (6)	No	Clinical	Yes	Yes	32% failed 20% died ca	33% died ca	16% died ca
Quinn et al. [18]	263	(56)	Yes (5)	Yes (99)	PSA ≥ 0.4 × 2	Yes	Yes	39% failed	32% 5-yr dfs	83% 5-yr dfs
Moul et al. [4]	162	(54)	Yes (1)	NR	PSA > 0.2 × 2	Yes	Yes	38%	39% 6-yr dfs	76% 6-yr dfs
Bauer et al. [19] same patients as [4]	175	(55)	Yes (1)	NR	PSA > 0.2 × 2	Yes	Yes	38%	45% failed 5-yr dfs 49%	23% failed 5-yr dfs 78%
Brewster et al. [20]	76	(38)	NR	No	PSA ≥ 0.2 × 2	Yes	Yes	30%	41% failed	21% failed
Goto et al. [21]	119	40	NR	No	PSA > 0.2	No	No	13% failed	40% failed	10% failed
Miyake et al. [9]	193	63	Yes (13)	No	PSA > 0.2	Yes	No	21% failed 5-yr dfs 79%	NR	NR
Wu et al. [23]	70	36.5	NR	NR	PSA > 0.2 × 2	No	No	30%	44% failed	26% failed
Osman et al. [24]	86	65	NR	Yes (33)	3 × PSA increase	NR	Yes	NR	0 5-yr dfs	68% 5-yr dfs

BCL-2
Bauer et al. [19]	175	(55)	Yes (1)	NR	PSA > 0.2 × 2	Yes	Yes	38% failed	57% failed 5-yr dfs 33%	31% failed 5-yr dfs 69%
Bauer et al. [19]	175	(55)	Yes (1)	NR	PSA > 0.2 × 2	Yes	Yes	38% failed	BCL2+ P53+ 5-yr dfs 25%	BCL2− P53− 5-yr dfs 80%
Brewster et al. [20]	76	(38)	NR	No	PSA > 0.2 × 2	Yes	Yes	30%	53% failed	24% failed
Goto et al. [21]	119	40	NR	No	PSA > 0.2	No	No	13% failed	21% failed	10% failed
Bubendorf et al. [22]	137	(64)	Yes (34)	Yes (60)	PSA, PAP, ALKP	NR	No	19% failed 5 yr dfs 78%	10-yr dfs 18%	10-yr dfs 52%
Miyake et al. [9]	193	63	Yes (13)	No	PSA > 0.2	No	No	21% failed	NR	NR
Wu et al. [23]	70	36.5	NR	NR	PSA > 0.2 × 2	Yes	Yes	30%	67% failed	28% failed

NR: not reported.
Most studies include clinical failure: biopsy-proven local recurrence and/or radiographic distant metastasis in addition to PSA.